




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12Q 1/68	A1	(11) International Publication Number: WO 94/29484 (43) International Publication Date: 22 December 1994 (22.12.94)
<p>(21) International Application Number: PCT/US94/06658</p> <p>(22) International Filing Date: 8 June 1994 (08.06.94)</p> <p>(30) Priority Data: 08/074,345 9 June 1993 (09.06.93) US</p> <p>(71) Applicant: IMAGEN INCORPORATED [US/US]; 4th floor, 50 Staniford Street, Boston, MA 02109 (US).</p> <p>(72) Inventor: MIAN, Alec; 137 Magazine Street, Cambridge, MA 02139 (US).</p> <p>(74) Agent: NOONAN, Kevin, E.; Allegretti & Witcoff, Ltd., Ten South Wacker Drive, Chicago, IL 60606 (US).</p>	<p>(81) Designated States: AU, CA, JP, KR, NO, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	

(54) Title: **MAGNETIC CYCLE REACTION**

(57) Abstract

The invention provides a process for amplification of specific nucleic acid sequences based upon the separation of nucleic acid strands by an electromagnetic field. This means of separation allows the use of mesophilic polymerases in the amplification process, thereby increasing the speed and fidelity of the amplification process, as well as the size of target nucleic acid that can be amplified.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

MAGNETIC CYCLE REACTION

BACKGROUND OF THE INVENTION

1. Field of the Invention

5 The invention relates to the amplification of specific nucleic acid sequences. More particularly, the invention relates to reagents and processes for carrying out such specific amplification, and to uses thereof.

2. Summary of the Related Art

10 The ability to amplify specific DNA sequences has greatly facilitated developments in the fields of molecular biology, medicine and forensics. Early processes for amplifying specific DNA sequences, known as PCR, utilized alternating cycles of thermal denaturation of double-stranded DNA molecules followed by reduced temperature annealing of primers to the single strands and
15 extension of the primers by a polymerase to again yield double strands. Mullis, U.S. Patent No. 4,683,202 (1987) discloses such a process, in which new polymerase must be added between cycles to replace the polymerase that has been inactivated by the elevated temperatures of the thermal denaturation step. Mullis
20 *et al.*, U.S. Patent No. 4,683,195 (1987) teaches the use of such a process to detect the presence or absence of a specific nucleic acid sequence in a sample, or to distinguish between different specific nucleic acid sequences in a sample.

 These early processes suffered from the considerable inconvenience of having to add polymerase enzyme between cycles. This inconvenience was overcome by the discovery of a purified thermostable DNA polymerase. Gelfand
25 *et al.*, U.S. Patent No. 4,889,818 (1989) discloses a purified thermostable polymerase enzyme from the thermophilic bacterium *Thermus aquaticus*. Mullis *et al.*, U.S. Patent No. 4,965,188 (1990) discloses a process for amplifying specific DNA sequences using the thermostable polymerase, thereby eliminating the need to add polymerase between reaction cycles. Johnson *et al.*, U.S. Patent
30 No. 5,038,852 (1991) discloses an apparatus for automating the polymerase chain reaction using the thermostable polymerase enzyme.

 The use of a thermostable polymerase enzyme in a thermal denaturation-based chain reaction has reduced the inconvenience of amplifying specific nucleic

- 2 -

acid sequences and has helped the method attain broad commercial acceptance. Unfortunately, the use of the thermostable enzyme, which is made necessary by the thermal denaturation step, has imposed serious limitations upon the amplification process. Foremost among these limitations are the fidelity of the amplification process, the size of the nucleic acid sequence that can be amplified, and the time required to carry out the amplification process. The thermostable polymerase enzyme is more prone to errors in the primer extension reaction than are many known polymerases from mesophilic sources. This can be a considerable problem when the amplification process is used preparatively for cloning. In addition, the thermostable polymerase enzyme has been used successfully to amplify nucleic acid sequences of only about 10 kilobases or less. Finally, the thermostable polymerase enzyme polymerizes deoxyribonucleoside triphosphates at a very slow rate. Coupled with the not inconsiderable time required for the thermal denaturation and annealing steps, this slow polymerization results in an amplification process that is measured in hours.

There is, therefore, a need for processes for amplifying specific nucleic acid sequences that overcome the limitations of the thermal cycle-based processes. Ideally, such a process should decrease the time required for the amplification process as well as the size of the target nucleic acid that can be amplified. Most preferably, such a process should rely upon equipment that is mechanically relatively simple.

SUMMARY OF THE INVENTION

The invention provides a process for amplification of specific nucleic acid sequences that is faster than existing methods, has greater fidelity, and can amplify much larger target nucleic acids. This new process is hereby designated "magnetic cycle reaction", or "MCR". The advantages of MCR arise from its use of electromagnetism to effect the strand separation necessary for amplification. Using electromagnetism for strand separation eliminates the need to carry out the amplification process under conditions that destabilize polymerase enzymes. Consequently, the invention provides the convenience of non-stop cyclic amplification of specific nucleic acid sequences without requiring the use of a

- 3 -

thermostable enzyme, and instead, mesophilic polymerase enzymes can be used. These mesophilic polymerases catalyze sequence extension at a rate that is at least one and one half orders of magnitude faster than that of the known thermostable polymerases. Moreover, the mesophilic polymerases have much greater fidelity of replication than the thermostable polymerases. In addition, the mesophilic polymerases are far more processive than the thermostable enzymes, allowing the amplification of target nucleic acids up to 100 or more kilobases in length. Thus, the invention provides specific nucleic acid amplification that is faster and more accurate than existing non-stop methods, and that is applicable to much larger target nucleic acid sequences.

The invention achieves electromagnetic separation of nucleic acid strands by utilizing primer types having two different kinds of bound particles. The first primer type is called "solid phase primer" and has the primer physically bound to a solid phase or immobile particle or surface. The second primer type is called a "magnetic primer" and is actually a primer that is physically bound to a particle that is responsive to an electromagnetic field. In the initial steps of the process according to the invention, the solid phase and magnetic phase primers are incorporated into the target nucleic acid sequences, into strands known as the solid phase strand and the magnetic strand. For single-stranded target sequences, this step requires one round each of polymerase extension from the solid phase and magnetic primers, with a single intervening denaturation step. For double-stranded target nucleic acid sequences, the same initial polymerase primer extension steps are used, but each is preceded by a denaturation step. These steps result in a target nucleic acid that has one end attached to a solid phase (via the 5' end of the solid phase strand) and one end attached to a magnetic particle (via the 5' end of the magnetic strand). Once such a target nucleic acid is obtained, amplification is carried out by multiple cycles of first applying a magnetic field to separate the solid phase and magnetic strands, then allowing additional solid phase and magnetic primers to anneal to the separated strands, then finally carrying out conventional polymerase extension from the annealed primers.

The amplification process according to the invention is useful for a variety of purposes. First, the process can be used for diagnostic purposes to determine

methods not only due to its greater rapidity, but also because the greater fidelity of the mesophilic polymerases results in fewer mutations in the preparative substrate. In addition, the amplification process according to the invention can be used for nucleic acid mapping, an application that is not possible using existing amplification methods. This use is made possible by the greater processivity of the nucleic acids up to 100 to 200 kilobases in length, compared with the maximum of about 5-10 kilobases obtainable with the less processive thermostable polymerases. This use of the amplification process according to the invention should supplement or replace existing mapping procedures, such as the yeast artificial chromosome cloning approach.

Certain preferred embodiments of the amplification process according to the invention are described in greater detail in the following sections of this application and in the drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic representation of the basic steps of the magnetic cycle reaction using a double-stranded target nucleic acid. Steps 1 and 2 are denaturation and extension steps. Long solid lines represent the initial target nucleic acid strands. Short solid lines represent primers. Stars and circles at the end of the primers represent attached magnetic particles and solid phase surfaces, respectively. Dashed lines represent primer extension products. Step 5 represents

- 5 -

electromagnetic pulse separation of target strands, and is followed by annealing of additional magnetic and solid phase primers and polymerase-mediated extension of the primers.

Figure 2 shows a general schematic representation of how the electromagnetic separation of the magnetic particle-bound and solid phase-bound target strands is achieved. A solenoid, 1, is wrapped around a test tube, 2, in which the amplification process takes place. Application of an electric pulse through the solenoid in one direction creates a magnetic field in the direction of the long arrow, 3. Attachment of one target strand to the solid phase surface, 4, prevents mobility of that strand in response to the magnetic field. In contrast, the other target strand is separated from the first target strand by the magnetic field due to its attachment to a magnetic particle, 5. Reversal of the electric pulse creates a magnetic field in the opposite direction, represented by the short arrow, 6, which returns the magnetic particle-bound strands and primers, 7, to the vicinity of the solid-phase bound target strands.

Figure 3 shows the experimental scheme used in the experiments described in Example 6. The Figure shows two representative wells of type A (well A) and B (well B) onto each of which a plurality of 750 nucleotide single-stranded DNA molecules have been covalently attached at the 5' of each DNA molecule. The DNA molecules in wells B are radioactively labeled (indicated by an asterisk), while those of wells A are not. In the second step of the experimental protocol, a plurality of 500 nucleotide single-stranded DNA molecules complementary to the 3' extent of the covalently-attached 750 nucleotide DNA molecules are annealed to the 750 nucleotide DNA molecules in each of the wells A and B. The 500 nucleotide DNA molecules are biotinylated at their 5' ends, and non-covalently attached to streptavidin-coated magnetic beads. These DNA molecules are then extended using T7 DNA polymerase in step 3 of the protocol in the presence (wells A) or absence (wells B) of radiolabeled nucleotide precursors. In step 4, the two DNA strands are separated at 50°C by the application of an external magnetic field, and the separated, extended, magnetic bead-linked strands isolated for electrophoretic analysis. After this separation, the wells were eluted at 90°C and DNA recovered for electrophoretic analysis.

- 6 -

Figure 4 shows the results of electrophoretic analysis of the DNA fragments produced according to Example 6. The first electrophoretic pattern on the left was produced by electrophoresis of radiolabeled 750 nucleotide template DNA and is shown as a control. The positions of the electrophoretic well origin, and of the 750 and 500 nucleotide DNA fragments, are indicated by arrows. The electrophoretic patterns of the DNA recovered by magnetic strand separation (50°C) and thermal denaturation (90°C) from each of the wells A and B are shown.

10 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The invention relates to the amplification of specific target nucleic acid sequences. The invention provides new reagents and a new process for carrying out such specific nucleic acid amplification.

In the first aspect, the invention provides an improved method for carrying out amplification of specific target nucleic acid sequences that is faster than existing methods, has greater fidelity, and can amplify much larger target nucleic acids. These improvements over existing amplification processes arise from the use of electromagnetism to effect the strand separation necessary for amplification. Accordingly, this new process is designated "magnetic cycle reaction" or "MCR".

The basic steps involved in the MCR process for amplifying a single-stranded target nucleic acid sequence are as follows. First, a solid phase or magnetic primer is incorporated into a nucleic acid strand that is complementary to the target nucleic acid sequence. This step yields a double stranded target nucleic acid that has one strand bound to either a solid phase or magnetic primer, respectively, the solid phase strand or the magnetic strand. Second, the target nucleic acid sequence and its complement are denatured. Third, a magnetic or solid phase primer, whichever was not incorporated into the complementary strand, is incorporated into a nucleic acid strand that is homologous to the target nucleic acid sequence, *i.e.*, complementary to the solid phase or magnetic strand. These steps provide a double-stranded nucleic acid sequence that has one strand bound to a solid phase primer (the solid phase strand) and another strand bound

- 7 -

to a magnetic primer (the magnetic strand). Fourth, the two strands are separated from each other by applying a magnetic field, in which the solid phase is immobile and the magnetic strand is mobile. Fifth, the separated strands are allowed to anneal to additional solid phase and magnetic primers. In this step, the solid phase strand is allowed to anneal to a magnetic oligonucleotide primer that is complementary to its 3' end, and the magnetic strand is allowed to anneal to a solid phase primer that is complementary to its 3' end. Sixth, the primers that are annealed to the solid phase strand and magnetic strand are extended by a polymerase to provide additional copies of double-stranded nucleic acids that have one strand bound to a solid phase primer and one strand bound to a magnetic primer. Seventh, steps four through six are repeated as many times as necessary to obtain a desired quantity of nucleic acid copies.

The basic steps involved in the MCR process for amplifying a double-stranded target nucleic sequence are the same as for amplifying a single-stranded target nucleic acid sequence, except for the following modifications in the initial steps. Initially, a prefatory denaturation step is necessary to separate the two target nucleic acid strands from each other. Then, the separated target nucleic acid strands are allowed to anneal to primers, with one strand annealing to a solid phase primer and the other strand annealing to a magnetic primer. Next, the primers are extended by a polymerase. These prefatory steps provide two double-stranded target nucleic acids, one of which has one solid phase strand and the other one magnetic strand. The remainder of the process is carried out as described above in steps two through seven for amplification of a single-stranded target nucleic acid.

For purposes of the invention, the term "incorporating a solid phase or magnetic primer into a nucleic acid strand" means hybridizing such a primer to a nucleic acid strand that is complementary to the strand to be synthesized, then extending the primer with a polymerase enzyme in the presence of deoxyribose or ribose nucleoside triphosphates.

For purposes of the invention, the term "magnetic primer" means an oligonucleotide primer that is covalently attached to a particle that is responsive to a magnetic field. Examples of preferred particles for use in such magnetic

- 8 -

primers include ferritin molecules and any other metallic particle that is large enough to have a dipole moment, such as Dynabead™ paramagnetic beads (Dynel, Oslo, Norway). The particle should be of a sufficient size to impart a maximum force that will separate the strand bound to the particle from a immobile complementary strand attached to a solid phase. For any given particle, the velocity can be determined empirically and maximum force calculated by the Stoke's relation:

$$F_M = 6\pi nrv$$

where r is the particle's radius, n is the viscosity of the buffer used for amplification and v is the unbound particle's measured velocity through the buffer. For purposes of the invention, the term "solid phase primer" means an oligonucleotide primer that is attached to a solid or immobile phase. In a preferred embodiment the solid phase is controlled pore glass (CPG) and the primer is covalently attached to the solid phase in the conventional manner used for synthesizing oligonucleotides. In another preferred embodiment, the primer is indirectly attached to the solid phase via a receptor-ligand interaction. In this embodiment, a receptor is covalently attached to a solid phase and its ligand is covalently attached to the primer, or *vice versa*. Thus, the primer becomes bound to the solid phase through the non-covalent receptor-ligand binding. Since binding to the solid phase should be very strong, the receptor-ligand affinity should be very high, such as that of the avidin-biotin system, which has an affinity of about 10^{15} /mole. Primers according to the invention are preferably covalently attached to the magnetic particle, solid phase surface, receptor, or ligand. Such attachment may be by a variety of means, and in a preferred embodiment involves the 5' hydroxyl group of the oligonucleotide. The length of the primers is generally the ordinary length for primers used in well-known polymerase chain reaction, and preferably is from about 8 to about 50 nucleotides. For purposes of the invention, a "magnetic strand" is a nucleic acid strand having an incorporated magnetic primer and a "solid phase strand" incorporated solid phase primer.

In the method according to the invention, the denaturation of double-stranded target nucleic acid prior to incorporation of both solid phase and magnetic primers may be carried out in a variety of ways. In one preferred

- 9 -

embodiment, such denaturation can be achieved thermally, for example, by
subjecting the sample to a temperature of 94°C for about one to about five
minutes, preferably for about 2 minutes. In an alternative embodiment, such
denaturation can be achieved by exposure of the sample to base, preferably at a
5 pH of from about 13 to about 14. In the first case, subsequent annealing of the
solid phase or magnetic primers to the separated strands is achieved by lowering
the temperature to below the T_m , usually from about 45°C to about 65°C for up
to 5 minute sin the presence of excess primer. In the second case, annealing is
carried out in the presence of excess primer by bringing the sample to neutral pH,
10 preferably from about pH 7 to pH 9. In either case the molar excess of primer
over target nucleic acid is preferably about 10^3 -fold for cloned target nucleic acids
and about 10^6 -fold for genomic target nucleic acids, and most preferably with a
primer concentration of about 100 picomoles per reaction. In either case, an
appropriate polymerase enzyme is then added in the presence of
15 deoxyribonucleoside or ribonucleoside triphosphates. Appropriate polymerases
include any RNA or DNA polymerase from any eukaryotic or prokaryotic
organism or virus. Preferred polymerases include T7 DNA polymerase and the
E. coli DNA polymerase holoenzyme or Klenow fragment. Preferably, the
nucleoside triphosphates are deoxyribonucleoside triphosphates and are present at
20 the concentration of about 100-300 μ M for each dNTP. Most preferably the
primer extension takes place in a buffer also containing about 5-15mM Mg^{2+} ,
1mM dithiothreitol (DTT), 0.5mM each of solid phase and magnetic primers, 0-
5mM betaine, and having a pH of about 7-8 due to the presence of about 10-
20mM Tris-HCl or HEPES buffer at that pH.

25 Once a solid phase primer has been incorporated into one strand of the
target nucleic acid and a magnetic primer has been incorporated into the opposite
strand, all further stand separation steps can be undertaken by application of an
electromagnetic field. As shown in Figure 2, attachment of one strand to a solid
or immobile phase and pulling of the other strand by an electromagnetic force
30 results in disruption of the base stacking and hydrogen bonding interactions
between the strands, culminating in strand separation. The electromagnetic force
applied to the double-stranded target nucleic acid should be sufficiently strong to

- 10 -

disrupt the base stacking and hydrogen bonding interactions between the strands, but not so strong as to disrupt covalent bonding interactions within the individual strands.

The force necessary to break the weakest intrastrand bond in a DNA molecule is about 368,000 joules/mole, or about 6×10^{-19} joules/molecule. Since work (W) = force (F) x distance (D), then the minimum force necessary to cause intrastrand scission is $F = W/D$. For DNA, the distance through which the force acts is 3.3×10^{-10} meters/molecule (see Smith *et al.*, 1992, *Science* 258:1122-1126). Thus, the minimum strand scission force,

$$F_s = \frac{6 \times 10^{-19} \text{ j/molecule}}{3.3 \times 10^{-10} \text{ m molecule}} = 1 \times 10^{-9} \text{ joule/mole} = 1 \times 10^{-9} \text{ Newton (N)}.$$

In contrast, the force necessary to disrupt a DNA duplex molecule is based upon the principal equation:

$$2f / [1-f]^2 C_o = \exp (-\Delta G^\circ/RT),$$

where C_o = concentration of single-stranded DNA;

$f = 0.9$ when $T = T_{90}$ (90% dissociated temp.);

$f = 0.5$ when $T = T_{50}$ (50% dissociation temp. = T_m);

and $f = 0.1$ when $T = T_{10}$ (10% dissociation temp.).

The temperature dependence of ΔG follows the integrated form of the Gibbs-Helmholtz equation:

$$\Delta G = -T\Delta S + \Delta H.$$

Thus, for a 200-mer,

$$\Delta G^\circ = 31.4 - \Delta G + (\text{initiation energy}) = 26.5 \text{ kcal/mole}$$

$$\Delta S^\circ = 0.32928 \text{ kcal/mole}$$

$$\Delta H^\circ = 148.8 \text{ kcal/mole and}$$

$$\Delta G_{90} - \Delta G_{10} = 31 \text{ kcal/mole, or about } 2 \times 10^{-19} \text{ joules/molecules.}$$

Thus,

$$F_D = \frac{2 \times 10^{-19} \text{ joules/molecule}}{3.3 \times 10^{-10} \text{ m/molecule}} = 6.1 \times 10^{-10} \text{ N}.$$

According to these value, the dissociation force, F_D , does not approach the scission force, F_s , until the duplex to be dissociated reaches about 600 b.p. At

- 11 -

well below this size range, however, duplex dissociation becomes cooperative, allowing complete dissociation without ever reaching F_S .

As indicated, it is beneficial to carry out dissociation at a temperature near the T_m of the duplex. However, the dissociation should occur at a temperature that does not destabilize the polymerase enzyme used for primer extension. Accordingly, it is preferable to use agents that lower the T_m of the duplex. For example, the zwitterion betaine, at $>5M$ concentration, shifts the melting temperature of calf thymus DNA from about $62^\circ C$ to about $48^\circ C$, without affecting protein-DNA interactions at neutral pH. Thus, in a preferred embodiment, MCR is carried out in a buffer containing $>1M$ betaine, most preferably from about $5.2M$ to about $5.6M$ betaine. Alternatively, melting temperature can be reduced by the presence of about $2.4M$ triethyl-ammonium chloride. It should be noted that the use of such agents to reduce melting temperature is generally more desirable when either longer target nucleic acids or target nucleic acids having higher G + C content are involved. Further destabilization of the double helix can be achieved by the addition of single strand binding (ssb) proteins, such as *E. coli* ssb, and/or helicases, such as *E. coli* DNA helicases I, II, and IV (see Wood and Matson, 1987, *J. Biol. Chem.* 262: 152-169 and 1989, *J. Biol. Chem.* 264: 82-97). Other chemicals denaturants can also be added in limited quantities to further reduce melting temperature. These denaturants include lower alkyl (1-4 C) alcohols, urea, formamide, and other hydrogen bond competitors. When such chemical denaturants are used, care must be taken to use them in quantities that will not excessively destabilize the polymerase enzyme. Such agents, used properly, can actually have the opposite effect. For example, 10% ethanol actually stabilizes the polymerase enzyme. The combination of various hydrogen bond destabilizing agents in the MCR reaction buffer allows the melting temperature of the target nucleic acid to be reduced such that the MCR can be carried out at a temperature just below the DNA melting temperature, but at which mesophilic polymerases remain stable and active. Carrying out MCR under these conditions ensures that the force required to separate the target nucleic acid strands is well below that level at which intrastrand covalent bond scission occurs.

- 12 -

In a second aspect, the invention provides a rapid quantitative assay for determining the abundance of a specific target nucleic acid in a sample. Such quantitative assays are well known for use with the polymerase chain reaction. (See *e.g.*, Noonan *et al.*, 1990, *Proc. Natl. Acad. Sci. USA* 87: 7160-7164). The method according to the invention, MCR, can simply be used in place of PCR in the well known quantitative assay that can be carried out in considerably less time than existing assays, due to the speed of MCR, relative to PCR.

In a third aspect, the invention provides an improved process for preparative generation of substrate nucleic acid molecules for cloning, sequence analysis, or mutagenesis. The method according to the invention provides such substrates having fewer mutations than those produced by current amplification procedures, due to the greater fidelity of the mesophilic polymerases. Consequently, the method according to the invention provides more reliable substrates for subsequent molecular biology manipulations.

In a fourth aspect, the invention provides a method for conducting long range genomic mapping. This is made possible by the ability of mesophilic polymerases to amplify target nucleic acids in the 100 to 200 kilobase size range. Currently, mapping over this size range can be carried out only by the somewhat cumbersome cloning of DNA into yeast artificial chromosomes (YACs). The ability to amplify such large target nucleic acid regions, however, provides a simpler approach. As sequence tag sites (STSs) are identified within the genome at 50-100 kb intervals (*see, e.g.* Olson *et al.*, 1989, *Science* 245: 1434-1435), the regions between consecutive STSs can conveniently be amplified by the method according to the invention, thereby providing a substrate for more fine-scale mapping by conventional procedures.

The following examples are intended to further illustrate certain preferred embodiments of the invention and are not limiting in nature.

- 13 -

EXAMPLE 1**Determination of the Actual Maximum
Force Provided by a Particular
Magnetic Particle In An Electromagnetic Field**

Dynabead™ paramagnetic beads are obtained from Dynal, Oslo, Norway. The maximum magnetic force acting on the bead is determined by measuring the bead's velocity when traveling through a buffering a microchamber in response to an electromagnetic field. The microchamber is constructed from a glass slide and sealed coverslip, with the volume between the two occupied by MCR buffer (see Example 4, below). The bead is placed at one end of the sealed, fluid-filled chamber. The slide is then surrounded with a solenoid through which current is passed to create the electromagnetic field. A computer cursor is superimposed on the microscope image and used to record the bead's velocity. since there is variation between beads, this measurement is taken for several beads. Velocity measurements are made for field strengths that theoretically impose a force upon the bead of 10^{-10} , 5×10^{-9} , 10^{-8} , 5×10^{-8} , 10^{-7} and 5×10^{-7} Newtons. The actual maximum force for the average of several beads is then determined by averaging the observed velocities of the beads and applying the Stokes' relation

$$F_M = 6\pi\eta r v$$

where r is the bead's radius, η the buffer viscosity, and v the bead's velocity. This value is then compared with the theoretical force that the electromagnetic field should have imposed upon the beads, and is thus used to calibrate the electromagnetic field to be used in each of the following examples.

EXAMPLE 2**Determination of the Minimum Force
Required to Cause Intrastrand
Covalent Bond Scission**

Prior to removal of the 5' dimethoxytrityl (DMT) group, a 50-mer oligodeoxynucleotide is biotinylated at its 3' hydroxyl by standard procedures. The DMT group is then removed in aqueous acetic acid and the oligonucleotide purified on C_{18} HPLC. A glass microscope slide is coated with

- 14 -

alkylamidopropanoic acid according to standard procedures. The biotinylated oligonucleotide is then esterified directly to the carboxyl moiety of the alkylamidopropanoic acid. Next, avidin conjugated Dynabead™ paramagnetic beads are added to the objective portion of the slide and unbound beads are rinsed away. The objective portion of the slide is then flooded with MCR buffer (see Example 4) and a coverslip is added. The slide is wrapped in a solenoid, and an electromagnetic field of appropriate strength to generate an actual force of 10^{-10} N on each bead is generated by directing electrical current through the solenoid. The actual force is increased until the oligonucleotides undergo scission at a force of about 10^{-9} N.

$$F = W/D = \frac{6 \times 10^{-19} \text{ j/molecule (for lowest bond dissociation energy in DNA)}}{3.3 \times 10^{-10} \text{ m (maximum extension of single internucleotide linkage)}}$$

Therefore, $F = \sim 2 \times 10^{-9} \text{ joule/molecule} = \sim 2 \times 10^{-9} \text{ N}$.

EXAMPLE 3

20 Determination of the Minimum Force Necessary for Destabilization of an Oligonucleotide Double Helix

A 3' levulinyl oligonucleotide (50-mer, same as in Example 2) is esterified directly via its 5' hydroxyl to the carboxyl group of alkylamidopropanoic acid coated glass microscope slide. The levulinyl protective group is then removed in base. A 5'-paramagnetic bead-derivatized 50-mer oligonucleotide having its 10 most 3' nucleotides complementary to the 10 most 3' nucleotides of the glass-bound oligonucleotide is then added in MCR buffer containing T7 DNA polymerase (see Example 4). Extension of the oligonucleotide produces a 90-mer duplex. A coverslip is added and the microscope slide is wrapped in a solenoid and placed on a microscope stage. Electrical current is then directed through the solenoid to generate an actual force upon the paramagnetic beads of about 10^{-10} N. This force is gradually increased until the strands of the duplex are separated at a force of about 6.1×10^{-10} N.

- 15 -

EXAMPLE 4**Amplification Protocol for Amplifying a Target
DNA Sequence using MCR**

5

The pBluescript™ SK+1- vector is linearized with *Pvu*II and a 210 b.p. fragment spanning the polylinker is amplified as follows. One ng digested plasmid is added to an Eppendorf tube containing a solution containing 15mM Tris-HCl (pH 7.5), 10mM MgCl₂, 1mM dithiothreitol (DTT), 0.2mM dNTPs, 10 0.5mM solid phase primer and 0.5 mM betaine.

The solid phase primer is 5'-AACAGCTATGACCATG-3' (SEQ ID No.:1), with the 5' hydroxyl group esterified to the carboxyl group of alkylamidopropanoic acid-controlled pore glass. The magnetic primer is 5'-GTAAAACGACGGCCAT-3' (SEQ ID No.:2), with the 5' end biotinylated and 15 linked to a streptavidin-derivatized Dynabead™. The solution is heated to 97°C for 2 minutes, then allowed to cool to 50°C. Ten units of T7 DNA polymerase is then added and the solution is incubated at 45°C for 2 minutes. The solution is heated to 97°C for 2 minutes, then again cooled to 50°C. Ten units of T7 DNA polymerase is added and the solution is again incubated at 45°C for two 20 minutes. The solution is transferred to an MCR machine, with the eppendorf tube fitting within a solenoid at a temperature of 45-50°C. An electromagnetic field of a strength that separates the strands of a duplex, but does not cause scission within a strand (*e.g.*, a field imparting upon each magnetic bead an actual maximum force between about 5×10^{-11} and 1×10^{-9} N) is then applied for 15 seconds; then reversed 25 for 5 seconds, and the solution is incubated at 45-50°C for two minutes. These electromagnetic pulse and incubation steps are then repeated about 20 times. The resulting 210 bp amplified product is then analyzed on gel electrophoresis.

30

- 16 -

EXAMPLE 5

**Amplification of a Target
DNA Sequence using MCR**

5

An MCR reaction mixture was assembled containing 30 attomoles of linear lambda phage DNA (~100pg) in a solution of 15mM Tris HCl (pH 7.5), 12mM MgCl₂, 50mM NaCl, 1mM dithiothreitol, 0.05mM of each dNTP, 5% glycerol, 5% ethylene glycol, 0.1% TWEEN detergent, and 0.5mM of each of two oligonucleotide primers. One of these primers was the magnetic primer, which is biotinylated at its 5' end and attached non-covalently to streptavidin-coated paramagnetic beads (Dynabead™). The nucleotide sequence of the magnetic primer was:

10

5'-CGAACAGGTTATCGAATTCAGCCAC-3' (SEQ ID No.:3).

15

The other primer was the solid phase primer which is covalently attached by the 5' terminal phosphate group to the bottom of a well of a microtitre dish (Covalink, Nunc Inc., Naperville, IL) comprising the reaction vessel in which MCR amplification was performed. The nucleotide sequence of the solid phase primer was:

20

5'-CATCGTCGTGTATTCCGGACAGTAC-3' (SEQ ID No.:4):

The MCR reaction mixture was heated to 94°C for 1 min, cooled to 50°C and 1-2 Units T7 DNA polymerase was added. Incubation at 50°C was continued for about 1 min. The solution was then heated to 94°C for about 1 min and cooled to 50°C and placed into an MCR apparatus as described above.

25

1-2 Units of T7 DNA polymerase were added to the MCR reaction mixture and incubated at 45-50° C for the duration of the MCR amplification. An electromagnetic field generated by a solenoid of the MCR apparatus was applied for about 15 sec and then the polarity of the field was reversed for about 5 sec followed by incubation in the absence of the external magnetic field for 5 sec. This cycle of electromagnetic pulses and incubations were repeated an additional 20 times. The resulting 750 bp DNA product was then eluted from the Dynabeads in a solution of 90% formamide/10mM EDTA and analyzed by gel electrophoresis. The results of such electrophoretic analysis confirmed amplification of a specific, 750 bp MCR product.

30

- 17 -

EXAMPLE 6**Demonstration of Strand Separation
using Electromagnetic Force**

5 The ability of a force generated by an applied electromagnetic field having field strength generated by the MCR apparatus described above to separate the strands of a 750 bp double-stranded DNA molecule was determined. Additionally, the assay used for this determination was also used to detect whether any strand scission accompanied DNA duplex denaturation.

10 The experimental scheme for this assay is shown in Figure 3. Two types of microtitre wells were prepared. In both wells, about 0.2 picomole of a 750 nucleotide, single-stranded DNA fragment was covalently linked to the microtitre well. In wells A, this DNA fragment was unlabeled, while in wells B the DNA fragment was radioactively labeled at its 5' end. Each of the 750 nucleotide
15 fragments in these wells was annealed with a 500 nucleotide, single-stranded DNA molecule complementary to the 3' 500 nucleotides of the 750 nucleotide fragment. The 500 nucleotide fragment was biotinylated at its 5' end and non-covalently linked to streptavidin-coated magnetic beads. T7 DNA polymerase was added in the presence of appropriate buffers, salts and dNTPs and the 500 nucleotide
20 fragment was extended. In wells A, extension was performed in the presence of (³²P)-labeled dCTP, while in wells B no radioactive dNTPs were present. After extension, the extended strands were separated by the application of an external magnetic field as described above at 50°C. The extended product was then eluted from the Dynabeads with a formamide solution as in Example 5 and analyzed by
25 electrophoresis. The wells are then heated to 90°C and the resulting supernatants also analyzed electrophoretically.

 The results of these experiments are shown in Figure 4. A sample of the radiolabeled 750 nucleotide template is shown for comparison. In the samples from wells A, radiolabeled (extended) DNA is seen in a broad smear from 500-
30 750 nucleotides, representing the population of DNA molecules extended to varying extents. Further thermal denaturation at 90°C shows essentially no additional radiolabeled DNA, indicating that magnetic separation was quantitative in these experiments. Wells B show no radiolabeled DNA at either 50° or 90°C,

- 18 -

indicating that magnetic separation was achieved without significant strand scission, and that covalent attachment of the radiolabeled template strand is stable to heating at 90°C.

5 These results demonstrate that DNA fragments at least 750 nucleotides in length can be quantitatively separated using an external magnetic field without concomitant strand scission, as predicted from the theoretical discussion presented in Examples 1-3.

10 It should be understood that the foregoing disclosure emphasizes certain specific embodiments of the invention and that all modifications or alternatives equivalent thereto are within the spirit and scope of the invention as set forth in the appended claims.

- 19 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: Gamera Bioscience
- (B) STREET: 30 Memorial Drive
- (C) CITY: Cambridge
- (D) STATE: Massachusetts
- (E) COUNTRY: USA
- (F) POSTAL CODE (ZIP): 02142
- (G) TELEPHONE: 617-441-1079
- (H) TELEFAX: (617)-441-1010

(ii) TITLE OF INVENTION: Magnetic Cycle Reaction

(iii) NUMBER OF SEQUENCES: 4

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

(v) CURRENT APPLICATION DATA:

APPLICATION NUMBER: PCT/US94/

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AACAGCTATG ACCATG

16

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

- 20 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GTAAACGAC GGCCAT

14

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CGAACAGGTT ATCGAATTCA GCCAC

25

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CATCGTCGTG TATCCGGAC AGTAC

25

- 21 -

I claim:

1. A method of amplifying a specific single-stranded target nucleic acid, the method comprising the steps of:
 - 5 (a) incorporating into a nucleic acid strand complementary to the target nucleic acid a solid phase primer to create a solid phase strand bound to the target nucleic acid;
 - (b) separating the solid phase strand and the target nucleic acid;
 - (c) incorporating into a nucleic acid strand complementary to the solid
10 phase strand a magnetic primer to yield a duplex having one solid phase strand and one magnetic strand;
 - (d) separating the solid phase strand from the magnetic strand by applying an electromagnetic field of sufficient strength to dissociate the duplex;
 - (e) allowing magnetic primers complementary to the solid phase strand
15 to anneal to the solid phase strand and allowing solid phase primers complementary to the magnetic strand to anneal to the magnetic strand;
 - (f) extending the annealed primers with a suitable DNA polymerase;
and
 - (g) repeating steps (d) through (f) as many times as necessary to obtain
20 a desired quantity of amplified DNA.
2. A method of amplifying a specific single stranded target nucleic acid, the method comprising the steps of:
 - (a) incorporating into a nucleic acid strand complementary to the target
25 nucleic acid a magnetic primer to create a magnetic strand bound to the target nucleic acid;
 - (b) separating the magnetic strand and the target nucleic acid;
 - (c) incorporating into a nucleic acid strand complementary to the magnetic strand a solid phase primer to yield a duplex having one solid phase
30 strand and one magnetic strand;

- 22 -

(d) separating the solid phase strand from the magnetic strand by applying an electromagnetic field of sufficient strength to dissociate the duplex;

(e) allowing magnetic primers complementary to the solid phase strand to anneal to the solid phase strand and allowing solid phase primers complementary to the magnetic strand to anneal to the magnetic strand;

(f) extending the annealed primers with a suitable DNA polymerase; and

(g) repeating steps (d) through (f) as many times as necessary to obtain a desired quantity of amplified DNA.

3. A method of amplifying a specific double stranded target nucleic acid, the method comprising the steps of:

(a) separating the strands of the target nucleic acid to yield a first strand and a second strand;

(b) incorporating a solid phase primer into a strand complementary to the first strand to yield a first heteroduplex having the first strand and a solid phase strand, and incorporating a magnetic primer into a strand complementary to the second strand to yield a second heteroduplex having the second strand and a magnetic strand;

(c) separating the strands of the first heteroduplex and of the second heteroduplex;

(d) allowing magnetic primers complementary to the solid phase strand to anneal to the solid phase strand and allowing solid phase primers complementary to the magnetic strand to anneal to the magnetic strand;

(f) extending the annealed primers with a suitable DNA polymerase; and

(g) repeating steps (d) through (f) as many times as necessary to obtain a desired quantity of amplified DNA.

4. The method according to claim 2, wherein the magnetic primer is an oligonucleotide bound to a ferritin molecule.

- 23 -

5. The method according to claim 1, wherein the magnetic primer is an oligonucleotide bound to a paramagnetic bead.

5 6. The method according to claim 1, wherein the solid phase primer is an oligonucleotide bound to a glass matrix.

7. The method according to claim 2, wherein the magnetic primer is an oligonucleotide bound to a ferritin molecule.

10

8. The method according to claim 2, wherein the magnetic primer is an oligonucleotide bound to a paramagnetic bead.

9. The method according to claim 2, wherein the solid phase primer is an oligonucleotide bound a glass matrix.

15

10. The method according to claim 3, wherein the magnetic primer is an oligonucleotide bound to a ferritin molecule.

11. The method according to claim 3, wherein the magnetic primer is an oligonucleotide bound to a paramagnetic bead.

20

12. The method according to claim 3, wherein the solid phase primer is an oligonucleotide bound to a glass matrix.

25

13. The method according to claim 1, wherein the method takes place in a buffer comprising:

30

- (a) from about 10 to about 20mM Tris-HCl (pH 7-8);
- (b) from about 5 to about 15 mM MgCl₂;
- (c) about 1mM DTT;
- (d) from about 0.1 to 0.3 mM each of 4 dNTPs;

- 24 -

- (e) about 0.5mM solid phase primer; and/or
- (f) about 0.5 mM magnetic primer; and
- (g) from about 0 to about 5.6M betaine; and
- (h) target nucleic acid.

5

14. The method according to claim 2, wherein the method takes place in a buffer comprising:

- (a) from about 10 to about 20mM Tris-HCl (pH 7-8);
- (b) from about 5 to about 15 mM $MgCl_2$;
- 10 (c) about 1mM DTT;
- (d) from about 0.1 to 0.3 mM each of 4 dNTPs;
- (e) about 0.5mM solid phase primer; and/or
- (f) about 0.5 mM magnetic primer; and
- (g) from about 0 to about 5.6M betaine; and
- 15 (h) target nucleic acid.

15. The method according to claim 3, wherein the method takes place in a buffer comprising:

- 20 (a) from about 10 to about 20mM Tris-HCl (pH 7-8);
- (b) from about 5 to about 15 mM $MgCl_2$;
- (c) about 1mM DTT;
- (d) from about 0.1 to 0.3 mM each of 4 dNTPs;
- (e) about 0.5mM solid phase primer; and/or
- 25 (f) about 0.5 mM magnetic primer; and
- (g) from about 0 to about 5.6M betaine; and
- (h) target nucleic acid.




Figure 1


Figure 2



3/4

Figure 3

4/4

Figure 4

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 94/06658

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,93 09250 (ADELAIDE CHILDREN'S HOSPITAL) 13 May 1993 the whole document ---	1-15
A	WO,A,92 06216 (BOEHRINGER MANNHEIM GMBH) 16 April 1992 the whole document ---	1-15
A	WO,A,92 05443 (MEDICAL RESEARCH COUNCIL) 2 April 1992 the whole document ---	1-15
A	WO,A,92 04470 (SCIENTIFIC GENERICS LIMITED) 19 March 1992 the whole document ---	1-15
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

21 September 1994

Date of mailing of the international search report

19. 10. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Hornig, H

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 94/06658

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO,A,93 15224 (SCIENTIFIC GENERICS LIMITED) 5 August 1993 the whole document -----	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 94/06658

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9309250	13-05-93	CA-A- 2122450	13-05-93
WO-A-9206216	16-04-92	DE-A- 4038804	16-04-92
		DE-A- 4041608	25-06-92
		AU-A- 8627591	28-04-92
		CA-A- 2093647	10-04-92
		EP-A- 0480289	15-04-92
		EP-A- 0552203	28-07-93
		JP-A- 4258299	14-09-92
		JP-B- 6040839	01-06-94
		JP-T- 6501157	10-02-94
WO-A-9205443	02-04-92	NONE	
WO-A-9204470	19-03-92	GB-A- 2247889	18-03-92
		AU-A- 8517391	30-03-92
WO-A-9315224	05-08-93	AU-B- 3362893	01-09-93